Sustained remissions with long-term weekly chlorambucil maintenance therapy in patients with mucosa-associated lymphoid tissue lymphoma.
Five patients with mucosa-associated lymphoid tissue (MALT) lymphoma (Helicobacter pylori negative) were initially treated with daily chlorambucil (Chl, 0.06-0.08 mg/kg per day) and achieved complete remission (n = 4) or partial remission (n = 1). They were then given long-term weekly Chl as maintenance therapy with good results. One patient came off treatment and has remained in continued remission for 44 months. This simple, low-cost, and convenient approach deserves further evaluation in patients with MALT lymphoma and other indolent and incurable lymphoproliferative disorders.
Manoharan
Arumugam
A
Department of Clinical Haematology, St. George Hospital, University of New South Wales, Sydney, Australia. a.manoharan@unsw.edu.au
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D002699:Chlorambucil